Clinical Trials Browser

Phase 1/2 × Tumor-Agnostic × 90 days × Clear all

NCT07630974 2026-06-05

MK-9999-01D

Phase 1/2 Not yet recruiting

Neoplasms

NCT05004116 2026-06-04

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07213817 2026-06-01

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07213830 2026-06-01

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT04145622 2026-05-29

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT02079740 2026-05-28

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

96 enrolled 30 charts

Neoplasm Metastasis

NCT07335497 2026-05-28

ASCEND

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT05384626 2026-05-27

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07193511 2026-05-26

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT05674825 2026-05-22

MCW I-PREDICT

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms

NCT06796907 2026-05-22

BEHOLD-2

Phase 1/2 Recruiting

Neoplasms

NCT02130492 2026-05-15

A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)

Phase 1/2 Suspended

Neoplasms

NCT04317105 2026-05-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT06941272 2026-05-12

MK-9999-01C

Phase 1/2 Recruiting

Neoplasms

NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT02908906 2026-05-08

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1/2 Active not recruiting

Neoplasms

NCT06818643 2026-05-08

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Phase 1/2 Recruiting

Neoplasms

NCT05394337 2026-05-05

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Phase 1/2 Recruiting

Neoplasms

NCT05898399 2026-05-01

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT03872778 2026-04-30

NeoRay

Phase 1/2 Completed

Neoplasms

NCT03535246 2026-04-24

Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

Phase 1/2 Recruiting

Neoplasms

NCT03614650 2026-04-24

Immunotherapy Treating GI Cancer

Phase 1/2 Recruiting

Neoplasms

NCT06077877 2026-04-24

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT05975073 2026-04-22

A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Phase 1/2 Completed

Neoplasms

NCT06614140 2026-04-22

Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors

Phase 1/2 Completed

Neoplasms

NCT05875168 2026-04-20

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT04799054 2026-04-13

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

Neoplasm Metastasis

NCT05120596 2026-04-13

First in Human Study of T3P-Y058-739 (T3P)

Phase 1/2 Recruiting

Neoplasms

NCT01968109 2026-04-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Phase 1/2 Completed

1,482 enrolled 56 charts

Neoplasms by Site

NCT06238687 2026-04-06

A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

Phase 1/2 Completed

Neoplasms

NCT07510828 2026-04-06

PRISM-NK

Phase 1/2 Recruiting

Neoplasms

NCT07276373 2026-04-03

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Phase 1/2 Recruiting

Neoplasms

NCT04713046 2026-04-02

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT05516914 2026-04-01

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Phase 1/2 Completed

Neoplasms

NCT07498725 2026-03-27

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors

Phase 1/2 Not yet recruiting

Neoplasms

NCT05046171 2026-03-24

Decreasing Polypharmacy in Older Adults With Curable Cancers Trial

Phase 1/2 Completed

Neoplasms